CHSS Responds to Genetic Testing Rollout for Clopidogrel 18 November 2025 Chest Heart & Stroke Scotland has welcomed the Scottish Government’s plans to roll out genetic testing for Clopidogrel, aimed at preventing future strokes for thousands of survivors. Jane-Claire Judson, CEO at Chest Heart & Stroke Scotland, said: “It is so encouraging to see the genetic testing of Clopidogrel being rolled out, particularly as it was signposted in the Programme for Government last year. It is reassuring to see the Scottish Government deliver on this important healthcare innovation. “We welcome this step forward in stroke care. Genetic testing to tailor treatment could be a gamechanger for thousands of people in Scotland who have survived a stroke or TIA. This quick and cost-effective blood test could prevent thousands of future strokes – saving lives, reducing long-term health and social care costs, and supporting the wellbeing of many people who live in fear of it happening again. “We now urge the Scottish Government and NHS Scotland to ensure this is implemented across the whole country as quickly as possible, so as many people as possible can benefit from this breakthrough.” Read more on this: Genetic test hopes to prevent future strokes for thousands of Scots survivors | STV News If you’re living with the effects of a chest, heart or stroke condition or Long Covid and are looking for advice and information, please contact Chest Heart & Stroke Scotland’s Advice Line on 0808 801 0899. You can also text ADVICE to 66777 or email adviceline@chss.org.uk.